Invited Talks

  1. ”Lagging behind in scientific development in Croatia and other EU13 countries – possible solutions at the national and EU level”, HAZU Round Table, New European initiatives for research and innovation within the project Alliance4Life_ACTIONS, December 13, 2022, Zagreb, Croatia
  2. ”Congenital cytomegalovirus infection – neuroinflammation and brain pathology mechanisms“, Middle European Societies for immunology and allergology (MESIA), November 23-26 2022, Prague, Czech Republic
  3. ”Immunization against SARS-CoV-2 using alternative routes and virus vectors“, FEMS Conference on Microbiology 2022, June 30 to July 2, Belgrade, Serbia
  4. ”Immunology and pathogenesis of congenital cytomegalovirus infection of CNS”, Infection Biology / Dynamics of host-pathogen interactions, annual PhD symposium, Hannover Medical School, zoom symposium, June 28-29, 2021
  5. ”Contemporary vaccines”, 4th Student’s health prevention congress – SANITAS 2021, Faculty of Medicine University of Rijeka, May 21-22, 2021, Rijeka, Croatia
  6. ”Imune reactivity during COVID-19”, HAZU: Applied genomics during Covid-19”, e-scientific meeting, April 27, 2021
  7. ”Scientific achievements and international impact of research in virology at the Faculty of Medicine in Rijeka”, COVID-19 Messages I: Advancement in virology research – an opportunity to improve international impac on the University of Rijeka, September 24, 2020, Rijeka, Croatia
  8. ”Innate immunity to viruses”, The SIICA School of Immunology 2020, Viral Immunology & Vaccinology, April 24, 2020, webinar
  1. ”Immune response and brain pathology following congenital CMV infection – mouse model”, Cluster of Excellence – ”From Regenerative Biology to Reconstructive Therapy”, Hannover Medical School, January 9-11, 2020, Hannover, Germany
  1. ”Microglia and NK cells – major players in brain inflammation and pathology following congenital cytomegalovirus infection”, Max Planck Institute for Infection Biology (MPIIB), November 20-21, 2019, Berlin, Germany
  1. ”Mayor players in brain inflammation and pathology in mouse model of congenital CMV infection.”, International Congres of Immunology IUIS2019, October 19-24, 2019, Beijing, China
  1. ”Therapeutic anti-tumor vaccines based on cytomegalovirus vector expressing NKG2D ligands”. Cancer and immunology meeting, October 15-18, 2019, Hefei, China
  1. ”CMV expressing NKG2D ligands as a tumor vaccine vector”, symposium: Tumor immune escape and resistance (TIMER) – EFIS 2019, Martin Luther University, October 8-9, 2019, Halle, Germany
  1. ”Pathogenesis of congenital CMV infection of central nervous system”, Power of microbes in industry and environment 2019, May 17-18 2019, Sv. Martin na Muri
  1. ”MCMV altered MHC I molecules in NK evasion and receptor evolution”, Washington University in St. Louis, April 12, 2019, St. Louis, Missouri, USA
  1. ”NK cells are major players in brain inflammation and pathology in congenital CMV infection”. 7th International Congenital CMV Conference & 17th International CMV Workshop, April 7-11, 2019, Birmingham, Alabama, USA
  2. ”Age dependance of the cerebral immune response after neonatal MCMV infection” 7th International Workshop on CMV and Immunosenescence, November 8 – 10, 2018, Waldthausen Castle, Mainz, Germany
  1. ”Can viruses teach us to make better vaccines? Immune response to cytomegalovirus expressing cellular ligands for innate immune receptors.”, 4th International Course of the international network in collaboration with Institut Pasteur of Rome and Paris: ”Persistent viral Infections and Immune Evasion”, July 10 – 11, 2018, Rome, Italy
  1. ”Critical role of NK cells in brain inflammation and pathology during congenital cytomegalovirus infection”, 17th Meeting of the Society for Natural Immunity NK2018, May 28 – June 1, 2018, San Antonio, Texas, USA
  1. ”Differential role of NK cells and tissue resident memory CD8 T cells in brain after congenital cytomegalovirus infection”, University Medical Center, Albert-Ludwigs-University Freiburg, March 26, 2018, Freiburg, Germany
  1. ”Brain-resident memory CD8 T cells induced by congenital CMV infection prevent brain pathology and virus reactivation”, Institute for virology and immunobiology, University of Wüerzburg, January 29, 2018, Wüerzburg, Germany
  2. ”Viral immuno-subversive mechanisms: can we make them work for us?” 1st International biomedical student congress Rijeka, Faculty of medicine University of Rijeka, November 2 – 4, 2017, Rijeka, Croatia
  3. ”Cytomegalovirus regulation of innate immune response”, International Retreat for PhD students in Immunology, October 6 – 7, 2017, Verona, Italia
  4. ”NK cells mediate microglia polarization during congenital CMV infection”, 42nd International Herpesvirus Workshop (IHW2017), July 29 – August 2, 2017, Ghent, Belgium
  5. ”Cytomegalovirus expressing NKG2D ligand Rae-1 gamma as a tumor vaccine vector”, Medical University of Vienna, May 18, 2017, Vienna, Austria
  6. ”Can viruses teach us to make better vaccine vectors – lessons from viral immunoevasion of innate immune receptors”, Immunology and Cancer Research Special Seminar, The Lautenberg Center for General The Faculty of Medicine and Tumor Immunology, The Hebrew University of Jerusalem-Hadassah Medical School, May 10, 2017, Jerusalem, Israel
  7. “From viruses to tumors – new smart vaccines in tumor therapy”, University hospital for infectious diseases “Dr. Fran Mihaljević” – ERC day, H2020 project Science Squared, Medical Faculty University of Zagreb, December 16, 2016, Zagreb, Croatia
  8. ”Cytomegalovirus evasion of DNAM-1 dependent immune control by inflammatory monocytes and NK cells”, annual meeting of the Croatian Immunological Society, October 14-15, 2016, Ogulin, Croatia
  9. ”Congenital cytomegalovirus infection and neuroinflammation”, HAZU symposium: Translation of Basic Immunology and Neuroscience Tools to Therapies: Where are we now?, July 4, 2016, Rijeka, Croatia
  10. ”Transcriptome analysis as a powerful tool for studying viral immune evasion strategy”, HAZU symposium – Applied genomics in the Republic of Croatia, May 17, 2016, Zagreb, Croatia
  11. ”CMV-based anticancer vaccines”, final training event Masterclass VacTrain, May 9 – 10, 2016, Leiden, Netherlands
  12. ”Viral regulation of PVR (CD155) reveals a robust capacity of DNAM-1 in cytomegalovirus control by mononuclear phagocytes and NK cells”, Serbian Immunological Society, April 27 – 28, 2016, Belgrade, Serbia
  13. ”Dynamics of CMV specific CD8 response in brain of mice infected as newborns”, ECCI – European Congenital Cytomegalovirus Initiative 2016, April 24 – 26, 2016, San Servolo, Venice, Italy
  14. ”Scientific research overview”, new membership election to EAM – European Academy of Microbiology Meeting, April 15 – 16, 2016, Segovia, Spain
  15. ”Viral regulation of PVR (CD155) reveals a robust capacity of DNAM-1 in cytomegalovirus control by macrophages and NK cells”, Humanitas research Institute, November 16, 2015, Milano, Italy
  16. ”Can viruses teach us to make better vaccine vectors? Immunological properties of cytomegalovirus expressing cellular ligands for innate immune receptors.” Glycovax kick-off meeting, November 9 – 10, 2015, Siena, Italy
  17. ”Regulation of CD8 T cell response to viral infection – lessons from cytomegalovirus immunoevasins”, SFB seminar, Institute for Immunology, Ludwig-Maximilian-University, Munich, October 22 – 23, 2015, Munich, Germany
  18. Personal statement on expectations to the political initiative of the Intergovernmental Initiative Western Balkans and the adjacent Joint Science Conference, 1st Joint Science Conference Western Balkans, Intergovernmental Initiative Western Balkans, Perspective Europe: building future with science, LEOPOLDINA, July 15 – 18, 2015, Halle, Berlin, Germany
  19. ”Pathogenesis of cytomegalovirus infection in brain of perinatally infected mice”, Workshop on challenges in developing immunotools for diagnostics and therapeutics, in frame of the project ”Molecular mechanisms of PVR (CD155) immunological pathways in viral and tumor pathogenesis” (PVRreg), June 15,  2015, Rijeka, Croatia
  20. “Vaccines and innate immunity: lessons from cytomegalovirus immunoevasion”, 3rd Belgrade  EFIS symposium on immunoregulation, immunity, infection, autoimmunity and aging, May 24-27, 2015, Aranđelovac, Serbia
  21. ”Cytomegalovirus downregulation of PVR reveals strong effect of DNAM-1 in virus control by NK cells and macrophages”, NK2015: 15th Meeting of the Society for Natural Immunity, May 2-6, 2015, Fairmont le Chateau Montebello, Quebec, Canada
  22. ”Pathogenesis of cytomegalovirus infection in ovary: Mechanisms of differential resistance of corpora lutea and follicles to infection”, 5th International Congenital CMV Conference and 15th International CMV/Betaherpesvirus Workshop, April 19-24, 2015,  Brisbane, Australia
  23. ”From basic discoveries to academic entrepreneurship in adverse economic conditions”, Educational Workshop: Biotech Business, Product Development and Entrepreneurship, Miltenyi Biotec GmbH, March 4, 2015, Bergisch Gladbach, Köln, Germany
  24. ”From basic discoveries in immunology to academic entrepreneurship: The role of science in the development of economy and society”,  Conference: The role of science in the development of society and economics, University of Split, January 28, 2015, Split, Croatia
  25. “NKG2D independent immune function of RAE-1: enhanced CD8 T cell response induced by CMV vector expressing RAE-1 gamma”, Deutsches Rheuma Forschungszentrum, January 15 – 17, 2015, Berlin, Germany
  26. ”Innate & Adaptive Immunity Interface”, 2nd Waldthausen Cytomegalovirus Symposium, University of Mainz, November 21 – 22, 2014, Waldthausen Castle, Budenheim, Germany
  27. ”Differential innate immune resistance of ovarian corpora lutea and follicles to

cytomegalovirus infection”, Croatian immunological society annual meeting, HID2014, October 17 – 18, 2014, Krk, Croatia

  1. ”Genetically modified and immunologically attenuated herpesviruses as potent vaccine vectors.”, Power of Viral Vectors in Gene Therapy and Basic Science Summer School, Croatian microbiological society, September 17 – 21, 2014, Primošten, Croatia
  2. ”CMV vaccine research – coupling the innate and adaptive immunity arms”, 2nd European Seminar in Virology, University of Bologna, June 13 – 15, 2014, Bertinoro, Italy
  3. ”Scientific career in adverse economic and social conditions”, 24th European Society of Clinical Microbiology and Infectious Diseases ECCMID2014, May 9 – 12, 2014, Barcelona, Spain
  4. ”Lecture of the ERC Advanced Grant holder”, National Institute of Chemistry, April 25, 2014, Ljubljana, Slovenia
  5. ”Upgrading the research capacity of the University of Rijeka, Faculty of Medicine through REGPOT”, conference “Experience of the REGPOT-PL projects in improving competence in the future EC projects’ management”, Warsaw University of Life Sciences, March 27, 2014, Warsaw, Poland
  6. “Enhancing the CD8 T cell response by RAE-1 gamma expressed in a herpesvirus vector – not only NKG2D”, Immunology Seminar, Cambridge Institute for Medical Research, February 14, 2014, Cambridge, Great Britain
  7. “Recognition of murine cytomegalovirus infected cells by activating an inhibitory Ly49 NK cell receptors”, Virus & Immunity course, Centre International de Recherche en Infectiologie (CIRI), INSERM, February 13, 2014, Lyon, France
  8. ”Expression of NKG2D ligand improves vaccine properties of recombinant cytomegalovirus”, PhD seminar on Institute of Immunology, Department of Pathobiology, University of Veterinary Medicine, November 28, 2013, Vienna, Austria
  9. ”Expression of NKG2D ligand RAE-1 gamma by recombinant cytomegalovirus enhances its immunogeneicity and vaccine efficacy”, PhD course on tumor immunology and immunotherapy, Center for Immunity and Infection Lausanne, Ludwig institute for cancer research, November 5, 2013, Lausanne, Switzerland
  10. ”Genetically modified herpesviruses as vaccine vectors”, CROCMID–10th Croatian congress of clinical microbiology and 7th Croatian congress on infectious diseases, October 24 – 27, 2013, Rovinj, Croatia
  11. ”Superior induction and maintenance of protective CD8 T cells with mouse cytomegalovirus vector expressing NKG2D ligand RAE-1y”, 2nd Meeting of Middle-European Societies for Immunology and Allergology, October 10 – 13, 2013, Opatija, Croatia
  12. ”Curious case of specific recognition of MCMV by NK cells: the role of uORFs and ncRNAs”, NK2013 – 14th Meeting of the Society for Natural Immunity, September  18 -22, 2013, Heidelberg, Germany
  13. ”Viral regulation of inhibitory and activating Ly49 receptors”, 15th International Congress of Immunology ICI2013, August 22 – 27, 2013, Milano, Italia
  14. ”Presentation of the first Croatian ERC Advanced Grant”, Croatian Science in the European Union,  Ministry of science, education and sport, July 12, 2013, Zagreb, Croatia
  15. ”NKG2D -dependent and -independent immune function of RAE-1: superior induction and maintenance of protective CD8 T cells in mice infected with MCMV vector expressing RAE-1” , Medical Immunology Campus Erlangen, July 1 – 2, 2013, Erlangen, Germany
  16. ”MCMV transcript with multiple coding and non-coding functions needed for recognition of infected cells by activating Ly49 NK cell receptors”, 4th CMI Symposium on Immunology: Innate Immunity and NK Cells, June 17 – 19, 2013, Hefei, Anhui Province, China
  17. ”Expression of NKG2D ligand by cytomegalovirus enhances virus immunogenicity and vaccine efficacy”, introductory lecture at the Meeting of class II, German National  Academy for Science Leopoldina,   May 22 – 23, 2013, Halle, Germany
  18. “Recognition of murine cytomegalovirus infected cells by activating an inhibitory Ly49 NK cell receptors”, International Graduate School in Molecular Medicine Ulm, April 11 – 13, 2013, Ulm, Germany
  19. “Differential requirements for activating and inhibitory Ly49 receptors in recognition of MCMV-infected cells”, ETH Zürich (Eidgenössische Technische Hochschule Zürich), February 27 – 28, 2013, Zürich, Switzerland
  20. “Strengthening adaptive immunity via innate immunity”, Doctoral School of Biomedicine–Department of Molecular Medicine, University of Padova, February 20, 2013, Padova, Italy
  21. “Herpesviruses as vectors – what did cytomegaloviruses teach us?”, 120th Anniversary of Immunological Society, November 20, 2012, Zagreb, Croatia
  22. “NK cells in MCMV infection – from no function to too many functions”, CMV Liaison Symposium, Max von Pettenfoker-Institut, November 16 – 18, 2012, Munich, Germany
  23. “Highly attenuated MCMV vector expressing NKG2D ligand RAE-1 gamma provides long-lived memory CD8+T cells with outstanding protective capacity”, 14th International CMV/BetaHerpesvirus workshop, October 29 – November 2, 2012, San Francisco, USA
  24. “Highly attenuated herpesvirus vector expressing NKG2D ligand RAE-1 provides long-lived memory CD8 T cells with outstanding protective capacity against Listeria monocytogenes“, 5th Croatian Congress of Microbiology with International Participation, September 26 -30, 2012, Primošten, Croatia
  25. “Highly attenuated herpesvirus vector expressing NKG2D ligand RAE-1 gamma provides long lived memory CD8+ T cells with outstanding protective capacity”, TWINCORE-Symposium, September 27 – 28, 2012, Hannover, Germany
  26. “Activating and inhibitory LY49 receptors have differential requirements for recognition of MCMV- infected cells”, European Congress of Immunology, September 5 – 8, 2012, Glasgow, Scotland
  27. “Highly attenuated herpesvirus vector expressing NKG2D ligand RAE-1 provides long-lived memory CD8 T cells with outstanding protective capacity”, Mikrobiologisch-Infektiologische Seminarreih, June 4 – 5, 2012, Virological Institute, Ulm, Germany
  28. “Genetic manipulation of viral genome as a tool to generate more efficient virus vaccine and vaccine vectors”, 3rd Congress of Croatian Geneticists, May 13 – 16, 2012, Krk, Croatia
  29. “Enhancing the adaptive immune response by the NKG2D ligand expressed in a herpesvirus vector”, 13th meeting of the Society for Natural Immunity, April 20 – 24, 2012, Asilomar, California, USA
  30. “Can we improve CD8 response to viral infection – lessons from cytomegalovirus expressing NKG2D ligand.”, Washington University, School of Medicine, April 18 – 19, 2012, Louis, USA
  31. “Vaccines and innate immunity: lessons from cytomegalovirus immunoevasion of NKG2D”, Final Symposium of the SFB 490 “Invasion and Persistence of Infectious Organisms”, March 8 – 10, 2012, Mainz, Germany
  32. “Regulation of inhibitory and activating LY49 receptors by murine cytomegalovirus”, Virus & Immunity course, Centre International de Recherche en Infectiologie (CIRI), INSERM, January 30 – February 10, 2012, Lyon, France
  33. “Vaccines and innate immunity: lessons from cytomegalovirus immunoevasion of NKG2D”, British Society of Immunology congress, December 5 – 9, 2011, Liverpool, UK
  34. “Immunobiology of a recombinant cytomegalovirus expressing the NKG2D ligand – an approach towards live attenuated vaccine and vaccine vector.”, Croatian Immunological Society, 2011 Annual Meeting, October 7 – 9, 2011, Rabac, Croatia
  35. “Viral interference with activating and inhibitory NK cell receptors.”, 3rd South East European Immunology School (SEEIS2011), October 1 – 4, 2011, Arandjelovac, Serbia
  36. “How can viruses teach us to make better vaccines and vaccine vectors”, 7th ISABS Conference in Forensic, Anthropological and Medical Genetics and Mayo Clinic Lectures in Translational Medicine, June 20 – 24, 2011, Bol, Island of Brač, Croatia
  37. “MCMV interference with activating and inhibitory LY49 NK cell receptors”, SFB900 seminar, June 16, 2011, Hannover Medical School, Germany
  38. “Recent advances in the pathogenesis of CMV infection”, 21st ECCMID/27th ICC 2011, May 7-10, 2011, Milan, Italy
  39. “Expression of NKG2D ligand improves vaccine properties of recombinant cytomegalovirus”, Natural Killer Cell Symposium, April 18-20, 2011, Mainz, Germany
  40. “Vaccine properties of recombinant herpesvirus expressing ligand for NKG2D receptor”, Annual Meeting of the Austrian Society for Allergology and Immunology 2010, December 3 – 5, 2010, Wien, Austria
  41. “Pathogenesis of CMV infection of the fetal brain”, 3rd Congenital Cytomegalovirus Conference, September 23 – 25, 2010, Paris, France
  42. “Cytomegalovirus protein m04 abolishes NK cells activation via the “missing-self” recognition mechanism, “Viral infection” Symposia, 14th International Congress of Immunology (ICI 2010), August 22 – 27, 2010, Kobe, Japan
  43. “Cytomegalovirus immunoevasin reveals the physiological role of “missing-self” recognitionin NK cell dependent virus control in vivo”, 35th Annual International Herpesvirus Workshop, July 24 -29, 2010, Salt Lake City, Utah, USA
  44. “Activation and inhibition of NK cells by murine cytomegalovirus – dual function of viral m04 protein”, Karolinska Instituet, October 8 – 11, 2009, Stockholm, Sweden
  45. Introduction lecture and Chair of the Workshop ‘Microbial Evasion of the Immune System’, 2nd European Congress of Immunology, September 13 – 16, 2009, Berlin, Germany
  46. “Viral inhibitors of NKG2D ligands”, Symposium ‘The MIC Genes and Antibodies -From Bench to Bedside’, 2nd European Congress of Immunology, September 13 – 16, 2009, Berlin, Germany
  47. “Immmunobiology of recombinant MCMV expressing ligand for NKG2D receptor”, Workshop ‘Receptors and regulation’; 7th Consortial Meeting EC6 Marie Curie Project ‘NK Defense and therapy’, September 10 – 11, 2009, Düsseldorf, Germany
  48. “Modes of regulation of NK cells by cytomegalovirus”, 5th Annual Meeting of the PhD Graduate Course GRK1045, August 24 – 26, 2009, Velen, Germany
  49. “Inhibition and activation of NK cells by murine cytomegalovirus”, Macroregional Network for Cell Therapy in Hematopoietic Stem Cell Transplant Recipients, University of Padova Medical School, April 26 – 27, 2009, Bressanone, Italy
  50. “Pathogenesis of congenital virus infection of the central nervous syste”, SISSA (Scuola Internazionale Superiore di Studi Avanzati), March 6, 2009, Trieste, Italy
  51. “The role of MCMV protein m04 in the regulation of NK cell”, 6th Consortial Meeting EC6 Marie Curie Project “NK Defense and Therapy”, Febuary 24, 2009, Wien, Austria
  52. “Activation and inhibition of NK cells by MCMV – the role of m04 protein”, Max von Pettenkofer-Institute, Ludwig Maximilian University, December 19, 2008, Munich, Germany
  53. “Regulation of NK cell response by cytomegalovirus – implications on viral pathogenesis”, Institut de Bacteriologie, Faculty of Medicine, University Louis Pasteur, November 27 –28, 2008, Strasbourg, France
  54. “The MCMV m04 protein plays a role in both the inhibition and activation of NK cells”, 11th Meeting of the Society for Natural Immunity:NK2008, October 26 – 30, 2008, Fremantle, Western Australia, Perth, Australia
  55. “Activation and inhibition of NK cells by murine cytomegalovirus”, Microbiology Seminar, Raine Medical Research Foundation, University of Western Australia, October 24, 2008, Perth, Australia
  56. “Pathogenesis of congenital cytomegalovirus infection of the central nervous system; insights from an animal model”, Raine Lecture, Raine Medical Research Foundation, University of Western Australia, October 22, 2008, Perth, Australia
  57. “Activation and inhibition of NK cells by murine cytomegalovirus”, 2008 Annual Meeting of the Croatian Immunological Society,October 9 – 12, 2008, Sibenik, Croatia
  58. “Activation and inhibition of NK cells by murine cytomegalovirus”, 2nd EFIS / EJI Belgrade Symposium (Inflamation at the Interface of Innate and Acquired Immunity), September 7 – 10, 2008, Belgrade, Serbia
  59. “Pathogenesis of congenital CMV infection:animal model”, 20th Annual Meeting of the EACD (European Academy of Childhood Disability), June 5-7, 2008, Zagreb, Croatia
  60. “Activation and inhibition of NK cell responses by murine cytomegalovirus”, EFIS – EJI Natural Killer Cell Symposium, May 21-23, 2008, Bad Herrenalb, Germany
  61. “Viral evasion of NK cell response”, ETH Institute of Microbiology, April 01, 2008, Zurich, Switzerland
  62. “NK cell immune evasion by murine cytomegalovirus”, Keystone Symposia, February 24-29, 2008, Keystone, Colorado
  63. “Downregulation of NKG2D ligands by CMV”, Annual Meeting of the French Society for Immunology: Immunity Infection and Vaccination, November 26 – 29, 2007, Lyon, France
  64. “Altered development and immune response of the brain following cytomegalovirus infection in newborn mice”, Centre d’Immunologie de Marseille-Luminy (CIML), November 23, 2007, Marseille, France
  65. “Viral regulation of innate immunity”, Waldthausen Castle Symposium Cytomegalovirus, Collaborative Research Centre 490, Gutenberg University, October 19 -20, 2007, Mainz, Germany
  66. “U.S. – Croatian scientific collaboration: the importance of the joint NIH funding”, Conference: Increasing U.S. – Croatian Cooperation in the ICT, Biotechnology and Pharmaceutical Industry, October 1 – 4, 2007, Split, Croatia
  67. “Regulation of NK cell responses by murine cytomegaloviruses”, Medical University Vienna Vienna Competence Center, June 29, 2007, Vienna, Austria
  68. “Regualtion of NK cell responses by cytomegaloviruses”, 5th National Conference SIICA Italian Society of Immunology, clinical immunology and allergology, June 6 – 9, 2007, Trieste, Italy
  69. “Viral immune evasion of NKG2D”, 94th Annual Meeting of the AAI: Immunology 2007, May 18 – 22, 2007, Miami – Florida, USA
  70. “Regulation of NK cell response by MCMV”, 11th International CMV & Betaherpesvirus workshop, May 13 – 17, 2007, Toulouse, France
  71. “Differential regulation of NKG2D ligands by MCMV”, Croatian – Israeli Kick-off Meeting on Viral Immunology and Pathogenesis, March 23, 2007, Rijeka, Croatia
  72. “Regulation of NK cell responses by murine cytomegalovirus”, Institut für Virologie, February 05, 2007, Düsseldorf, Germany
  73. “Different modes of NK cell regulation by MCMV”, Seminar SFB 455, Gene Center, December 13, 2006, Munich, Germany
  74. “Murine CMV infection models and potential therapies”, 2nd Consortium meeting EC project “NK defense and therapy”, November 17 – 18, 2006,Vienna, Austria
  75. “Down-regulation of NKG2D ligands by CMV”, 6th Louis Pasteur Conference on Infectious Diseases, “Shaping and Subversion of the immune system by Microbe”, The Institute Pasteur, November 15 – 17, 2006, Paris, France
  76. “Activation and inhibition of NK cells by murine cytomegalovirus”, 1st Mini-Herpesvirus Workshop, September 29, 2006, Berlin, Germany
  77. “Subversion of NK cell activation by murine cytomegalovirus”, Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia (CSIC), July 05, 2006, Madrid, Spain
  78. “Murine cytomegalovirus inhibits NK cell activation by down – modulation of cellular ligands for NKG2D receptor”, 2nd FEMS Congress of European Microbiologists, July 04– 08, 2006, Madrid, Spain
  79. “Murine CMV as a model for human CMV infection: principles of immunosurveillance and viral immunoevasion”, 2006 NIAID research conference, June 24 – 25, 2006, Opatija, Croatia
  80. “Innate immunity to cytomegalovirus and viral evasion of NK cell respons”, Virus and Immunity 2006, Febuary 6, 2006, Lyon, France
  81. “Evasion of NK cell control by murine cytomegalovirus”, The Institute for Microbiology and Hygiene, University of Freiburg, January 23, 2006, Freiburg, Germany
  82. “Evasion of NK cells by murine cytomegalovirus”, Institut für Klinische und Molekulare Virologie Nationales Referenzzentrum für Retroviren Friedrich-Alexander-Universität Erlangen-Nürnberg, January 20, 2006, Erlangen, Germany
  83. “Molecular and cellular approaches to microbial pathogenesis”, Summer school, The Graduate College “Mucosal Host-Pathogen- Interaction” of the School of Veterinary Medicine Hannover and the Medical School Hannover, October 4 – 6, 2005, Hannover, Germany
  84. “MCMV proteins which interfere with the expression of NKG2D ligands” International Titisee Conferences – Cell biology meets the immune system: molecular aspects of host pathogen interactions, April 6 – 10, 2005, Schwarzwald, Germany
  85. “Multiple strategies to evade NKG2D by MCMV”, Keystone Symposia – Innate Immunity to Pathogens, January 8 – 13, 2005, Keystone, Colorado, USA
  86. “Interplay of MCMV with NK cell response”, Max von Pettenkofer Institut, December 9, 2004, Munich, Germany
  87. “Immune evasion of viruses and tumors by downregulations of cellular ligands for NKG2D receptor”, 2nd Slovenian Immunology Congress with International Participation, October 20 – 22, 2004, Portorož, Slovenia
  88. “The importance of NK cell in transplantation”, 4th Croatian Congress of Infectious Diseases, October 2 – 6, 2004, Opatija, Croatia
  89. “Characterisation of cytomegalovirus genes involved in modulation of cellular ligands for NK cell receptors”, Congress of the Croatian Society of Biochemistry and Molecular Biology, September 30, 2004, Bjelolasica, Croatia
  90. “Molecular and functional characterisation of mouse cytomegalovirus genes involved in regulation of NK cell response”, EMBO Practical Course, Anatomy and Embryology of the Mouse, September11–19, 2004, Zagreb, Croatia
  91. “Murine cytomegalovirus subvert NK cell control by interfering with expression of NKG2D ligands”, Institute Pasteur, June 25, 2004, Paris, France
  92. “Regulation of NK cell response by BY murine cytomegalovirus”, Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, February 26, 2004, Würzburg, Germany
  93. “Modulation of NK cell response by murine cytomegalovirus”, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, January 22, 2004, Madrid, Spain
  94. “Deletion of MCMV m157 gene reveals the function of NKG2D silencing viral genes also in CMV1 positive mice”, Stimulatory and Inhibitory Receptors of the Innate Immune System, Instituto Juan March de Estudios e Investigaciones, Madrid, January 19 – 21, 2004, Madrid, Spain
  95. “Significance of stress-induced ligands for NKG2D receptor in NK cell- mediated surveillance of tumors and viral infectins”, Stress and immunoreactivity, HAZU, October 20, 2003, Zagreb, Croatia
  96. “Murine cytomegalovirus-mediated regulation of NK cell response”, University of Alabama, August 2003, Birmingham, Alabama, USA
  97. “Regulation of NK cell function by MCMV”, Department of Pathology, College of Medicine and Public health, The Ohio State University, July 25, 2003, Columbus, Ohio, USA
  98. “Immune evasion by cytomegaloviruses”, 1st Croatian Congress on Molecular Life Sciences, June 9 – 13, 2002, Opatija, Croatia
  99. “Regulation of NK cell activity by murine cytomegalovirus”, Veterinary University of Vienna, October 25, 2002, Vienna, Austria
  100. “The MCMV m152/GP40 glycoprotein downregulates expression of a cellular ligand for the NKG2D receptor and inhibits NK cell-mediated virus control in vivo”, Molecular Mechanisms of Immune Modulation: lessons from Viruses, February 25 – 27, 2002, Madrid, Spain
  101. “In vivo significance of MCMVevasion genes (M152, M06 AND M04) in regulation of CD8+ T cells response”, Department of Microbiology & Immunology, Fairchild Science Building, Stanford University School of Medicine, May 9, 2001, Stanford, California, USA
  102. “In vivo significance of MCMV evasion genes for MHC I”, Department of Pathology, College of Medicine and Public health, The Ohio State University, June 5, 2001, Columbus, Ohio, USA
  103. “Immune evasion of T cell and NK response by cytomegalovirus proteins”, 1st Slovenian Immunology Meeting – Immunology and Clinic III, Immunity inInfection, October 26 –28, 2000, Portorož, Slovenia
  104. “Cytomegaloviral evasion of T cell and NK cell responses”, 2nd Croatian Congress of Microbiology with International Participation, October 3 – 6, 2000, Brijuni, Croatia
  105. “Immunobiology and pathogenesis of murine cytomegalovirus deletion mutant”, Department of Immunology, The Scrips Research Institute, La Jolla, March 31, 1998, California, USA
  106. “In vivo significance of murine cytomegalovirus immunoevasion gene”, Department of Microbiology & Immunology, Fairchild Science Building, Stanford University School of Medicine, Stanford, March 23, 1998, Stanford, CA, USA
  107. “MCMV: true molecular latency or low-level persistence? The role ofT cell subsets andcytokines”, Human Cytomegalovirus Latencyand Reactivation, Weston La Paloma, March 20 – 21, 1998, Tuscon, USA
  108. “Immunopathology and TNF-alpha involvment in MCMV infection in newborn mice”, 1st International Consensus Round Table Meeting on CMV Related Immunopathology, August 28 – 30, 1997, Frankfurt, Germany
  109. “Characterization of immune mechanisms controlling recurrent cytomegalovirus infection”, The 3rd International Meeting “Mechanisms in Local Immunity”, September 25 – 28, 1996, Opatija, Croatia
  110. “Control of recurrent CMV by T cells, NK cells and cytokines”, Virologisches Seminar, Institut for Medical Virology, University of Heidelberg, August 31, 1995, Heidelberg, Germany
  111. “Plasticity of immune response”, The Annual Meeting – League for the development of molecular biology and biotechnology (MoBBEL), October, 6 -9, 1995, Tübingen, Germany
  112. “Cytomegalovirus persistance in salivary glands by evasion from immune control”, Mechanisms in Local Immunity, 2nd Alpe-Adria Immunology and Allergology Meeting, September 26 – 28, 1994, Opatija, Croatia
  113. “Adoptive transfer of immunity against cytomegalic virus infection and implication for otherinfections”, European Association for Study of the Liver (EASL) Meeting, Atena Symposia: “Potentials of adoptive immunotherapy in the treatment of viral and neoplastic diseases of the liver”, September 6 – 10, 1994, Athena, Greece
  114. “Antiviral antibodies are not essential for resolution of primary cytomegalovirus infection”, Hadassah Medical Organization, Liver unit, University of Jerusalem, Israel, April 1994, Jerusalem, Israel
  115. “The componenets of the immune response in control of viral infections”, Annual Meeting of Israeli Microbiological Society, Department of Microbiology and Immunology, Faculty of Health Science, Ben-Gurion University, April 1994, Beer-Sheva, Israel
  • Center for Proteomics, Faculty of Medicine, University of Rijeka
Braće Branchetta 20, 51000 Rijeka, Croatia
University of Rijeka / Faculty of Medicine / Center for Proteomics

© Copyright 2023 | All rights reserved | Web development: Intraweb d.o.o.